Veraxa Biotech AG (VRXA)

Veraxa Biotech AG is a Swiss biotechnology company developing protein-based cancer therapies. Its programs center on antibody-drug conjugates, which deliver a cytotoxic payload directly to tumor cells. It also works on bispecific antibodies designed to direct the immune system against cancer.

The company uses its own engineering technologies to build these molecules, with the aim of improving precision and widening the therapeutic window compared with earlier approaches. Its candidates are at preclinical and early clinical stages. Veraxa became publicly traded in the United States through a business combination with a special purpose acquisition company.

Its ordinary shares trade on the Nasdaq under the ticker VRXA.